ACAD
34.3
-0.68
-1.94%
AEMD
4.96
-0.15
-2.94%
APRI
0.342
-0.008
-2.3163%
ARNA
1.73
-0.01
-0.57%
ATEC
8.21
-0.42
-4.87%
CNAT
2.1
0.00
N/A%
CRXM
0.24
-0.03
-10.70%
CYTX
2.04
-0.08
-3.77%
DXCM
93.16
-0.75
-0.80%
GNMK
11.56
-0.14
-1.20%
HALO
11.98
0.00
N/A%
ILMN
178.47
0.00
N/A%
INNV
0.29
+0.01
+3.5357%
INO
9.44
0.00
0.00%
ISCO
1.84
-0.06
-3.16%
ISIS
57.56
0.00
N/A%
LGND
113.09
-2.69
-2.32%
LPTN
3.83
-0.06
-1.54%
MBVX
4.16
-0.56
-11.86%
MEIP
1.71
+0.02
+1.18%
MNOV
7.47
+0.37
+5.21%
MRTX
6.2
+0.32
+5.44%
MSTX
0.123
-0.004
-3.454%
NBIX
53.25
0.00
N/A%
NUVA
66.15
-0.62
-0.93%
ONCS
1.77
-0.01
-0.56%
ONVO
3.91
0.00
N/A%
OREX
3.24
-0.22
-6.36%
OTIC
17.13
-0.52
-2.95%
QDEL
22.17
-0.54
-2.38%
RCPT
231.96
0.00
N/A%
RGLS
3.42
-0.03
-0.87%
RMD
63.59
+0.34
+0.54%
SPHS
3.22
+0.26
+8.78%
SRNE
7.67
-0.1
-1.29%
TROV
4.63
-0.16
-3.34%
VICL
3.19
-0.06
-1.85%
VOLC
18
0.00
0.00%
ZGNX
10.35
-0.1
-0.96%
ACAD
34.3
-0.68
-1.94%
AEMD
4.96
-0.15
-2.94%
APRI
0.342
-0.008
-2.3163%
ARNA
1.73
-0.01
-0.57%
ATEC
8.21
-0.42
-4.87%
CNAT
2.1
0.00
N/A%
CRXM
0.24
-0.03
-10.70%
CYTX
2.04
-0.08
-3.77%
DXCM
93.16
-0.75
-0.80%
GNMK
11.56
-0.14
-1.20%
HALO
11.98
0.00
N/A%
ILMN
178.47
0.00
N/A%
INNV
0.29
+0.01
+3.5357%
INO
9.44
0.00
0.00%
ISCO
1.84
-0.06
-3.16%
ISIS
57.56
0.00
N/A%
LGND
113.09
-2.69
-2.32%
LPTN
3.83
-0.06
-1.54%
MBVX
4.16
-0.56
-11.86%
MEIP
1.71
+0.02
+1.18%
MNOV
7.47
+0.37
+5.21%
MRTX
6.2
+0.32
+5.44%
MSTX
0.123
-0.004
-3.454%
NBIX
53.25
0.00
N/A%
NUVA
66.15
-0.62
-0.93%
ONCS
1.77
-0.01
-0.56%
ONVO
3.91
0.00
N/A%
OREX
3.24
-0.22
-6.36%
OTIC
17.13
-0.52
-2.95%
QDEL
22.17
-0.54
-2.38%
RCPT
231.96
0.00
N/A%
RGLS
3.42
-0.03
-0.87%
RMD
63.59
+0.34
+0.54%
SPHS
3.22
+0.26
+8.78%
SRNE
7.67
-0.1
-1.29%
TROV
4.63
-0.16
-3.34%
VICL
3.19
-0.06
-1.85%
VOLC
18
0.00
0.00%
ZGNX
10.35
-0.1
-0.96%
Home » Archive by Category

Syndication

Custodian (La Jolla)

September 16, 2016 – 9:10 am

Job #: F341
Laboratory/Department: Facility Services
The Salk Institute Facility Service department is responsible for overseeing building maintenance, ground maintenance, the interior and exterior building systems, and grounds.
Position Descripti […

Material Handler (La Jolla)

September 16, 2016 – 9:05 am

Job #: F294
Laboratory/Department: Purchasing
Purchasing Services is responsible for securing required materials and/or services consistent with quality requirements, at the most economical price and delivery available.
Position Description:
Unde […

Biotech Roundup: CRISPR’s 3rd IPO, Gender Diversity, Buyouts & More

September 16, 2016 – 8:14 am

Across the nation, and even looking back into the past, health was in the headlines this week. Our presidential candidates were either recovering from pneumonia or talking up their health records….

[[Click headline to continue reading.]]

Vigilant Biosciences Announces Oral Presentation on Immunohistochemistry Analysis of CD44, EGFR, and p16 in Oral Cancer at the American Academy of Otolaryngology-Head and Neck Surgery Foundation 2016 Annual Meeting

September 16, 2016 – 7:06 am

OncAlertTM Oral Cancer and OncAlertTM Labs product lines will be showcased in booth #2343

FORT LAUDERDALE, Fla. and SAN DIEGO, Sept. 16, 2016 /PRNewswire/ — AAO-HNS Annual Meeting – Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced an oral presentation of data related to studies conducted to better understand the relationship between CD44, EGFR and p16 expression in oral cavity and oropharyngeal cancers, and whether particular patterns of CD44, EGFR and p16 staining are associated with overall and progression-free survival.

The studies, along with others, helped provide direction for the clinical development of Vigilant Biosciences OncAlert Oral Cancer and OncAlert Labs product lines as well as pipeline programs under development.

The study, titled, “Immunohistochemistry Analysis of CD44, EGFR, and p16 in Oral Cancer,” was conducted by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and demonstrated the ability to identify the presence of the tumor-initiating and stem cell associated biomarker CD44, together with total protein, to indicate an elevated risk for oral cancer, even prior to the observation of visual or physical symptoms.

The data will be presented in a podium presentation at the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) Foundation 2016 Annual Meeting & OTO EXPO, which will be held September 18-21, 2016 in San Diego, CA. Vigilant Biosciences will also be showcasing its OncAlert Oral Cancer and OncAlert Labs product lines at the EXPO in Booth #2343.

Details for the oral presentation are as follows:
Title: Immunohistochemistry Analysis of CD44, EGFR, and p16 in Oral Cancer
Presenter: Erin R Cohen, M.D.
Date: Monday, September 19, 2016
Time: 8:45 AM
Location: SDCC, Room 31A

The full schedule of events can be viewed at www.entannualmeeting.org.

In its 120th year, the AAO-HNSF Annual Meeting & OTO EXPO showcases the latest advances in the otolaryngologist-head and neck surgery, including new research findings, approaches, and treatment options. The annual meeting and expo draws more than 5,500 otolaryngology, medical experts, and professionals from around the world.

About Oral Cancer
According to the World Health Organization, there are more than 529,000 new cases of oral (lip, oral cavity and pharynx) cancer each year worldwide, with mortality rates that reach up to 292,000 deaths each year. In the United States, more than 48,000 individuals will be diagnosed with oral cancer this year with more than 9,500 deaths resulting from this disease, killing roughly one person per hour, 24 hours per day. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early detection (stage I and II) of oral cancer yields survival rates of up to 90 percent.

About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. The Vigilant Biosciences OncAlertTM Oral Cancer product line and OncAlert Labs product line include point-of-care and lab-based products and services that are simple, accurate and cost-effective and that can empower healthcare practitioners to improve potential outcomes through earlier intervention. The OncAlert Oral Cancer LAB Test and the OncAlert Oral Cancer RAPID Test are CE Marked and available in select international markets outside the U.S. The OraMarkTM Test is a Laboratory Developed Test that is only available in the U.S. exclusively through OncAlert Labs, LLC, a CLIA-certified laboratory and a member of the Vigilant Biosciences family of companies. For more information, visit www.vigilantbiosciences.com and www.oncalertlabs.com.

For more information or to set up a meeting with Vigilant Biosciences at AAO-HNS, please contact Jennifer Moritz at jmoritz@0to5.com.

PR00-0007

 

SOURCE Vigilant Biosciences, Inc.

Capricor Therapeutics Announces Pricing of Offerings of Common Stock

September 16, 2016 – 6:00 am

LOS ANGELES, Sept. 16, 2016 /PRNewswire/ — Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced the pricing of its offerings of 3,000,000 shares of its common stock at an offering price of $3.20 per share, before underwriting discounts. 2,687,500 shares of Capricor’s common stock will be purchased by the underwriters in an underwritten registered public offering and 312,500 shares will be purchased by Cedars-Sinai Medical Center, a stockholder of Capricor, from Capricor directly and not through the underwriters in a concurrent registered direct offering. Capricor has granted the underwriters a 30-day option to purchase up to an additional 403,125 shares of its common stock. The proceeds to Capricor from the offerings are expected to be approximately $8.7 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the underwriters’ option. All shares of common stock to be sold in the offerings are being offered by Capricor. The offerings are expected to close on or about September 21, 2016, subject to customary closing conditions.

Roth Capital Partners and National Securities Corporation, a wholly-owned subsidiary of National Holdings, Inc., are acting as joint book-running managers for the registered public offering.

The securities described above are being offered by Capricor pursuant to a shelf registration statement on Form S-3 (File No. 333-207149) previously filed with the Securities and Exchange Commission (the “SEC”) on September 28, 2015 and declared effective by the SEC on October 26, 2015. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement related to the underwritten registered public offering was filed with the SEC on September 15, 2016 and is available on the SEC’s website at www.sec.gov, and a final prospectus supplement related to each of the offerings will be filed with the SEC and will be available on the SEC’s website. When available, copies of the final prospectus supplement and the accompanying prospectus for the securities being offered in the underwritten registered public offering may also be obtained from Roth Capital Partners, LLC, 888 San Clemente, Newport Beach, CA 92660, (800) 678-9147, and National Securities Corporation, 410 Park Avenue, 14th Floor, New York, NY 10022, (212) 417-8164.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. Capricor’s lead candidate, CAP-1002, is a cardiac cell therapy that is currently being evaluated for the treatment of heart disease associated with Duchenne muscular dystrophy and myocardial infarction (heart attack). Capricor is advancing its proprietary exosome product candidate, CAP-2003, for the treatment of ophthalmic disorders and is exploring other therapeutic areas. Capricor’s portfolio also features Cenderitide, a dual natriuretic peptide receptor agonist, which may have application for the outpatient treatment of advanced heart failure and other potential indications.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, expectations with respect to the expected use of proceeds from the recently completed offering and the anticipated effects of the offerings, and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business are set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission on March 30, 2016, in its Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 28, 2015, and in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, as filed with the Securities and Exchange Commission on August 15, 2016. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 and Cenderitide are Investigational New Drugs and are not approved for any indications. Capricor’s exosomes technology has not yet been investigated in any clinical trial.

For more information, please contact:

Corporate
Capricor Therapeutics, Inc.
AJ Bergmann, Vice President of Finance
+1-310-358-3200
abergmann@capricor.com

Investor Relations
Argot Partners
Kimberly Minarovich
+1-212-600-1902
kimberly@argotpartners.com

Media
Argot Partners
Eliza Schleifstein
+1-917-763-8106
eliza@argotpartners.com

 

SOURCE Capricor Therapeutics, Inc.

Clinical Trial Manager / Sr. CTM – Xencor – San Diego, CA

September 16, 2016 – 4:45 am

Is an innovative biotechnology company located in the Los Angeles area (near Pasadena) and in San Diego. Clinical Trial Manager / Sr CTM….From Xencor – Fri, 16 Sep 2016 11:45:22 GMT – View all San Diego jobs

Research Associate – BioPhase Solutions – San Diego, CA

September 16, 2016 – 2:04 am

Plus minimum 2+ years full-time experience with in vitro cell biology and molecular biology assays in an academia or biotechnology environment….From BioPhase Solutions – Fri, 16 Sep 2016 09:04:58 GMT – View all San Diego jobs

Senior Recruiter – Etech Hi Inc. – San Diego, CA

September 16, 2016 – 12:58 am

Construction, Engineering, Biotechnology, Medical, Nursing, Insurance, Legal, Pharmaceutical, Environmental, Finance, Mortgage, Retail, IT or Technology – then… $100,000 a year
From Etech Hi Inc. – Fri, 16 Sep 2016 07:58:46 GMT – View all San Diego jobs

Manufacturing Associate III – Planet Pharma – San Diego, CA

September 15, 2016 – 11:11 pm

Title: Manufacturing Associate II – III Company: Pharmaceutical Duration: Permanent Location: San Diego, CA *Role: * The Manufacturing Associate is
From Indeed – Fri, 16 Sep 2016 06:11:06 GMT – View all San Diego jobs

Lab Tech II – Organovo – San Diego, CA

September 15, 2016 – 10:07 pm

The successful candidate must have an Associate’s Degree or BS in Biology, Biotechnology or a related field. Lab Tech Responsibilities:….
From Organovo – Fri, 16 Sep 2016 05:07:12 GMT – View all San Diego jobs